Home / Intelligence / Case Studies / Strategic Recommendations About Potential Actions to Shape Bone Health Policy
Trinity completed a detailed analogue assessment to understand how various stakeholders are involved in shaping health policies across markets.
Geographic Scope: 
Client Situation
The client wanted to identify best practices as well as the external stakeholders they should consider working with to efficiently shape global bone health policy.
Trinity’s Solution
Trinity conducted a systematic analogue disease area filtration to understand the disease areas where health policy development is most comparable to the bone health space.
Trinity then conducted exhaustive secondary research within each analogue disease area to understand the most relevant health policy shaping stakeholders, their actions, and consequent impact; leverage key learnings from each analogue disease area to inform bone health policy recommendations.
Deliverables
- Analogue selection and methodology
- High level executive summary explaining overall trends
- Analogue assessments for five disease areas of interest
- Recommendations for exploring partnerships in developing bone health policy
Project Outcomes & Impact
The client was able to understand the strategic actions they could take in order to shape bone health policy across several markets and define the success factors that drive stakeholder engagement in policy-shaping activities. The client was also able to develop compelling case studies in order to gather cross-functional buy-in.
Related Intelligence
Webinars
Most-Favored Nation Pricing Policy: Why One Size Doesn’t Fit All
September 25, 2025 | 1:00 – 2:00 PM ET
As U.S. leaders promote a drug pricing vision based on Most-Favored Nation (MFN) principles, ensuring that U.S. consumers have access to the best available prices among advanced nations, pharmaceutical companies are facing increased uncertainty and are evaluating strategic options. This session will bring together Trinity experts to discuss how this initiative could realistically lead to […]
Sign Up Now
Blog
A Shrinking Safety Net: OBBBA’s Ripple Effects on the Pharma Industry
President Trump signed the “One Big Beautiful Bill Act” (OBBBA) into law on July 4, 2025. The OBBBA is projected to reduce federal health spending by an estimated $900 billion[1] over the next decade. Central to the legislation is the estimated loss of insurance coverage for 16 million people[2], fundamentally reshaping access to care for […]
Read More
Webinars
Part D in Peril: The Inconvenient Math of IRA Part D Redesign
Available On Demand
Medicare Part D is undergoing its most significant transformation in decades largely driven by the IRA. What does this mean for pharmaceutical manufacturers? Join us for an engaging discussion with Max Hunt, Partner at Trinity, and special guest Dan Simenc, clinical and actuarial expert at Milliman, as they provide perspectives on recent developments and future expectations for Medicare Part D and Medicare Advantage.
Watch Now